Display options
Cite
Nishimura R, Taniguchi M, Takeshima T, et al. Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. Adv Ther. 2021;doi: 10.1007/s12325-021-01979-1.
Nishimura, R., Taniguchi, M., Takeshima, T., & Iwasaki, K. (2021). Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. Advances in therapy, . https://doi.org/10.1007/s12325-021-01979-1
Nishimura, Rimei, et al. "Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis." Advances in therapy vol. (2021). doi: https://doi.org/10.1007/s12325-021-01979-1
Nishimura R, Taniguchi M, Takeshima T, Iwasaki K. Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. Adv Ther. 2021 Nov 30; doi: 10.1007/s12325-021-01979-1. Epub 2021 Nov 30. PMID: 34846709.
Copy Download .nbib Format: NLM
Share it on

Adv Ther. 2021 Nov 30; doi: 10.1007/s12325-021-01979-1. Epub 2021 Nov 30.

Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis.

Advances in therapy

Rimei Nishimura, Mayumi Taniguchi, Tomomi Takeshima, Kosuke Iwasaki

Affiliations

  1. Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, Japan.
  2. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., 1-13-1, Kyobashi, Chuo-ku, Tokyo, Japan. [email protected].
  3. Milliman Inc., 8F, Kojimachi 1-chome Building, 1-6-2 Kojimachi, Chiyoda-ku, Tokyo, Japan.

PMID: 34846709 DOI: 10.1007/s12325-021-01979-1

Abstract

INTRODUCTION: Although metformin is recommended as a first-line treatment for patients with type 2 diabetes (T2D) in Western countries, no specific treatment is recommended in Japan, and various agents are used. Metformin has long been used at low doses in Japan, and information regarding its effect at the maximum maintenance dose is lacking. Here, we compared the efficacy and safety of metformin at 1500 mg/day with those of the other oral anti-diabetic drugs (OADs) approved in Japan.

METHODS: Randomized controlled trials comparing a change in hemoglobin A1c (HbA1c) from baseline at 12 weeks or later (ΔHbA1c) among OADs (including placebo) as a first-line treatment in adult patients with T2D were selected by systematic review with comprehensive searching of CENTRAL, MEDLINE, Ichushi Web, and EMBASE and manual searching of clinical trial registries. The ΔHbA1c and incidence of hypoglycemia were compared among OAD treatments using Bayesian network meta-analysis (NMA). The relative risk (RR) of the incidence of hypoglycemia was determined relative to that of placebo.

RESULTS: Forty-six randomized controlled trials were identified in the systematic review, and 37 studies, comprising 38 different types of treatments, including placebos, were selected for the NMA of ΔHbA1c. Compared with metformin 1500 mg/day, 20 OAD treatments were significantly less effective in reducing HbA1c from baseline (differences from metformin 1500 mg/day: 0.40-0.96%). Two treatments (glimepiride 2 mg/day and pioglitazone 45 mg/day) showed greater mean reductions in HbA1c from baseline than metformin 1500 mg/day (- 0.38% and - 0.03%), although these differences were not significant. Regarding the incidence of hypoglycemia, only pioglitazone 30 mg/day among 31 treatments showed a lower RR (< - 0.01), whereas 23 treatments showed a significantly higher RR (1.02-66.71) than metformin 1500 mg/day.

CONCLUSION: The NMA suggested a preferable efficacy and safety profile of metformin 1500 mg/day compared with the other OADs approved in Japan.

© 2021. The Author(s).

Keywords: Glycated hemoglobin A; Hypoglycemia; Metformin; Network meta-analysis; Oral anti-diabetic drug; Systematic review; Type 2 diabetes

References

  1. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669–701. - PubMed
  2. Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11:165–223. - PubMed
  3. Odawara M, Kawamori R, Tajima N, et al. Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2017;8:286–95. - PubMed
  4. Kameda T, Kumamaru H, Nishimura S, Kohsaka S, Miyata H. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators. Curr Med Res Opin. 2020;36:749–56. - PubMed
  5. Tamura Y, Kato H, Hiroi S, et al. A study on the prescription status of metformin and DPP-4 inhibitors in patients with type 2 diabetes mellitus in Japan. An analysis of data from health insurance administrative claims. Ther Res. 2017;38:1231–7 (Japanese). - PubMed
  6. Metgluco 250 mg. Approval application form. Sumitomo Dainippon Pharma Co., Ltd; 2008. https://www.pmda.go.jp/drugs/2010/P201000009/index.html . Accessed 20 August 2021. (Japanese) - PubMed
  7. Higgins JPT, Thomas J, Chandler J, et al. (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane; 2020. https://training.cochrane.org/handbook/archive/v6.1 . Accessed 20 Aug 2021. - PubMed
  8. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84. - PubMed
  9. Edited by Julian PT Higgins JS, Matthew J Page, Jonathan AC Sterne on behalf of the RoB2 Development Group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2): RoB2 Development Group; 2019. https://methods.cochrane.org/risk-bias-2 . Accessed 20 Aug 2021. - PubMed
  10. Kashiwagi A. Development of the HbA1c international standardization of HbA1c measurement in Japan Diabetes Society. Rinsho Byori. 2013;61:585–93 (Japanese). - PubMed
  11. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28. - PubMed
  12. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–34. - PubMed
  13. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309–17. - PubMed
  14. Monotherapy study of MP-513 in patients with type 2 diabetes. ClinicalTrials.gov identifier: NCT00998881. Updated February 21, 2014. https://clinicaltrials.gov/ct2/show/NCT00998881 . Accessed 20 Aug 2021. - PubMed
  15. A phase II confirmatory study of SMP-862 monotherapy in patients with type 2 diabetes mellitus. Japan Pharmaceutical Information Center identifier: JapicCTI-050090. Updated July 21, 2010. https://www.clinicaltrials.jp/cti-user/trial/ShowDirect.jsp?japicId=JapicCTI-050090 . Accessed 20 Aug 2021. - PubMed
  16. Kato T, Sawai Y, Kanayama H, et al. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes. 2009;117:593–9. - PubMed
  17. Fujitaka K, Otani H, Jo F, et al. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. Endocr J. 2011;58:425–32. - PubMed
  18. Mikada A, Narita T, Yokoyama H, et al. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. “The MASTER randomized, controlled trial.” Diabetes Res Clin Pract. 2014;106:538–47. - PubMed
  19. Tsurutani Y, Nakai K, Inoue K, et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study. Diabetes Obes Metab. 2018;20:2675–9. - PubMed
  20. Kaku K. Dose-ranging study of anagliptin in Japanese patients with type 2 diabetes: a multi-centre, randomized, placebo-controlled, double-blind, parallel-group study. Jpn Pharmacol Ther. 2012;40:973–84 (Japanese). - PubMed
  21. Hotta N, Kakuta H, Sano T, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetes Med. 1993;10:134–8. - PubMed
  22. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010;12:613–22. - PubMed
  23. Yokoyama H, Inoue T, Node K. Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. Diabetes Res Clin Pract. 2009;83:77–82. - PubMed
  24. Tanaka SI, Origasa H, Akanuma Y, Kikuchi M. Evaluation of glucose lowering effects of mitiglinide in type 2 diabetes patients: placebo-controlled, parallel group comparative dose-response study. Jpn Pharmacol Ther. 2007;35:S5–21 (Japanese). - PubMed
  25. Kosaka K, Kikuchi M, Tarui S, et al. Phase-III study of a novel hypoglycemic agent, AY4166, on NIDDM patients in Japan. (1): α-glucosidase inhibitor, voglibose-controlled multicenter double blind study. Clin Pharmacol Therapy. 1997;7:699–727 (Japanese). - PubMed
  26. Kaneko T, Baba S, Toyoda T, et al. Dose setting test of AD-4833 for non-insulin dependent diabetes mellitus (NIDDM) by only diet therapy. Double blind intergroup comparative studies by 4 doses. Jpn J Clin Exp Med. 1997;74:1250–77. - PubMed
  27. Yamada Y, Terauchi Y, Watada H, et al. Efficacy and safety of GPR119 agonist DS-8500a in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Adv Ther. 2018;35:367–81. - PubMed
  28. Kaku K. Efficacy and safety of anagliptin in Japanese patients with type 2 diabetes: a multi-centre, randomized, placebo- and active comparator-controlled, double-blind, parallel-group study. Jpn Pharmacol Ther. 2012;40:985–95 (Japanese). - PubMed
  29. Seino Y. Efficacy and safety of saxagliptin in Japanese patients with type 2 diabetes: two multi-centre, randomized, double-blind, placebo-controlled studies. Jpn Pharmacol Ther. 2014;42:503–18 (Japanese). - PubMed
  30. Kashiwagi A, Kazuta K, Takinami Y, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study: BRIGHTEN: double-blind randomized study of ipragliflozin to show its efficacy as monotherapy in T2DM patients. Diabetol Int. 2015;6:8–18. - PubMed
  31. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16:1102–10. - PubMed
  32. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65. - PubMed
  33. Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31:621–38. - PubMed
  34. Fujitani Y, Fujimoto S, Takahashi K, et al. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP). Diabetes Res Clin Pract. 2016;121:146–56. - PubMed
  35. Gantz I, Okamoto T, Ito Y, et al. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:1602–9. - PubMed
  36. Satoh H, Ohira T, Moriya C, et al. Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): a randomized, open-label, two-arm, parallel comparative trial. Diabetes Metab. 2017;43:550–3. - PubMed
  37. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12. - PubMed
  38. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57:383–94. - PubMed
  39. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab. 2010;12:700–8. - PubMed
  40. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27:1781–92. - PubMed
  41. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14:348–57. - PubMed
  42. Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–45. - PubMed
  43. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:810–8. - PubMed
  44. Inagaki N, Onouchi H, Sano H, Funao N, Kuroda S, Kaku K. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:125–32. - PubMed
  45. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30:1245–55. - PubMed
  46. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30:1231–44. - PubMed
  47. Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30:1219–30. - PubMed
  48. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, phase III study. Expert Opin Pharmacother. 2014;15:1501–15. - PubMed
  49. Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol. 2015;3:191–7. - PubMed
  50. Kurebayashi S, Watada H, Tanaka Y, Kawasumi M, Kawamori R, Hirose T. Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. Endocr J. 2006;53:213–7. - PubMed
  51. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–40. - PubMed
  52. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79:291–8. - PubMed
  53. Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5:382–91. - PubMed
  54. Kaneko T. Clinical evaluation of an insulin resistance-improving agent, AD-4833, in patients with non-insulin-dependent diabetes mellitus receiving diet therapy alone: a double-blind placebo-controlled study. Jpn J Clin Exp Med. 1997;74:1491–514 (Japanese). - PubMed
  55. Koh N, Hayashi K, Hosokawa T. Effects of glimepiride on blood glucose control and oxidative stress in patients with type 2 diabetes-a study by nagoya medical association. J New Rem Clin. 2010;59:363–73 (Japanese). - PubMed
  56. Kikuchi M, Iwamoto Y, Inagaki N, Yoshioka T, Mimori N, Ebina H. Clinical evaluation of vildagliptin in patients with type 2 diabetes: a multi-center, randomized, double-blind, placebo-controlled, parallel group comparative study. J New Rem Clin. 2010;59:121–36 (Japanese). - PubMed
  57. Kamiya F, Hayashi Y, Takeuchi T. The clinical usefulness of chronic administration of AO-128 for non-insulin dependent diabetes mellitus. Comparative test of double blind experiment for which a placebo is used. J Adult Dis. 1992;22:573–91. - PubMed
  58. Koiwai K, Inoue S, Shiki K, Taniguchi A. Efficacy and safety of empagliflozin monotherapy in Japanese patients with type 2 diabetes: a sub-analysis of randomized, 24-week, double-blind global clinical trial. Prog Med. 2015;35:1231–42 (Japanese). - PubMed
  59. Kawamori R, Kaku K, Hanafusa T, Oikawa T, Kageyama S, Hotta N. Dose response study of rapid-acting insulin secretagogue repaglinide (SUREPOST®) monotherapy in patients with type 2 diabetes mellitus late phase II randomized double-blind study. J Clin Therap Med. 2014;30:113–27 (Japanese). - PubMed
  60. Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes. 2002;51:2789–95. - PubMed
  61. The Japan Diabetes Society. [Treatment Guide for Diabetes 2018–2019]. Tokyo: Bunkodo; 2018. (Japanese). - PubMed
  62. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65. - PubMed
  63. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53. - PubMed
  64. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316:313–24. - PubMed
  65. Jia Y, Lao Y, Zhu H, Li N, Leung SW. Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials. Obes Rev. 2019;20:1–12. - PubMed
  66. Mannucci E, Naletto L, Vaccaro G, et al. Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: a network meta-analysis of randomized, active comparator-controlled trials. Nutr Metab Cardiovasc Dis. 2021;31:1027–34. - PubMed

Publication Types